0000014272-19-000212.txt : 20191127 0000014272-19-000212.hdr.sgml : 20191127 20191127173116 ACCESSION NUMBER: 0000014272-19-000212 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191120 FILED AS OF DATE: 20191127 DATE AS OF CHANGE: 20191127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AHMED NADIM CENTRAL INDEX KEY: 0001731193 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 191259189 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 4 1 wf-form4_157489385725608.xml FORM 4 X0306 4 2019-11-20 0 0000014272 BRISTOL MYERS SQUIBB CO BMY 0001731193 AHMED NADIM 430 E. 29TH STREET 14TH FLOOR NEW YORK NY 10016 0 1 0 0 President, Hematology Common Stock, $0.10 par value 2019-11-20 4 A 0 14819 0 A 14819 D Common Stock, $0.10 par value 2019-11-20 4 A 0 1966 0 A 1966 I 401(k) Option (right to buy) 19.55 2019-11-20 4 A 0 3255 0 A 2022-01-30 Common Stock, $0.10 par value 3255.0 3255 D Option (right to buy) 19.61 2019-11-20 4 A 0 10460 0 A 2022-04-30 Common Stock, $0.10 par value 10460.0 10460 D Option (right to buy) 19.72 2019-11-20 4 A 0 10464 0 A 2022-10-31 Common Stock, $0.10 par value 10464.0 10464 D Option (right to buy) 21.63 2019-11-20 4 A 0 16740 0 A 2022-12-17 Common Stock, $0.10 par value 16740.0 16740 D Option (right to buy) 26.6 2019-11-20 4 A 0 10463 0 A 2023-01-28 Common Stock, $0.10 par value 10463.0 10463 D Option (right to buy) 31.85 2019-11-20 4 A 0 6974 0 A 2023-04-29 Common Stock, $0.10 par value 6974.0 6974 D Option (right to buy) 38.35 2019-11-20 4 A 0 6975 0 A 2023-07-29 Common Stock, $0.10 par value 6975.0 6975 D Option (right to buy) 42.0 2019-11-20 4 A 0 6975 0 A 2023-10-28 Common Stock, $0.10 par value 6975.0 6975 D Option (right to buy) 43.85 2019-11-20 4 A 0 7440 0 A 2023-12-02 Common Stock, $0.10 par value 7440.0 7440 D Option (right to buy) 39.95 2019-11-20 4 A 0 6974 0 A 2024-02-03 Common Stock, $0.10 par value 6974.0 6974 D Option (right to buy) 47.12 2019-11-20 4 A 0 13949 0 A 2024-07-28 Common Stock, $0.10 par value 13949.0 13949 D Option (right to buy) 55.44 2019-11-20 4 A 0 6975 0 A 2024-10-27 Common Stock, $0.10 par value 6975.0 6975 D Option (right to buy) 62.67 2019-11-20 4 A 0 9350 0 A 2024-12-19 Common Stock, $0.10 par value 9350.0 9350 D Option (right to buy) 63.41 2019-11-20 4 A 0 7012 0 A 2025-02-02 Common Stock, $0.10 par value 7012.0 7012 D Option (right to buy) 58.78 2019-11-20 4 A 0 9350 0 A 2025-05-04 Common Stock, $0.10 par value 9350.0 9350 D Option (right to buy) 70.89 2019-11-20 4 A 0 9350 0 A 2025-07-27 Common Stock, $0.10 par value 9350.0 9350 D Option (right to buy) 61.01 2019-11-20 4 A 0 9350 0 A 2025-11-09 Common Stock, $0.10 par value 9350.0 9350 D Option (right to buy) 54.2 2019-11-20 4 A 0 9299 0 A 2026-02-01 Common Stock, $0.10 par value 9299.0 9299 D Option (right to buy) 56.44 2019-11-20 4 A 0 5812 0 A 2026-05-02 Common Stock, $0.10 par value 5812.0 5812 D Option (right to buy) 61.34 2019-11-20 4 A 0 5843 0 A 2026-08-01 Common Stock, $0.10 par value 5843.0 5843 D Option (right to buy) 54.94 2019-11-20 4 A 0 12205 0 A 2026-10-31 Common Stock, $0.10 par value 12205.0 12205 D Option (right to buy) 60.53 2019-11-20 4 A 0 12272 0 A 2027-01-30 Common Stock, $0.10 par value 12272.0 12272 D Option (right to buy) 66.35 2019-11-20 4 A 0 5843 0 A 2027-05-01 Common Stock, $0.10 par value 5843.0 5843 D Option (right to buy) 72.42 2019-11-20 4 A 0 5843 0 A 2027-07-31 Common Stock, $0.10 par value 5843.0 5843 D Option (right to buy) 54.29 2019-11-20 4 A 0 9300 0 A 2027-10-30 Common Stock, $0.10 par value 9300.0 9300 D Option (right to buy) 55.52 2019-11-20 4 A 0 9299 0 A 2028-01-29 Common Stock, $0.10 par value 9299.0 9299 D Option (right to buy) 44.7 2019-11-20 4 A 0 19619 0 A 2028-05-08 Common Stock, $0.10 par value 19619.0 19619 D Option (right to buy) 47.81 2019-11-20 4 A 0 19619 0 A 2028-07-30 Common Stock, $0.10 par value 19619.0 19619 D Option (right to buy) 38.41 2019-11-20 4 A 0 19621 0 A 2028-10-29 Common Stock, $0.10 par value 19621.0 19621 D Restricted Stock Units 2019-11-20 4 A 0 2908 0 A 2020-05-01 Common Stock, $0.10 par value 2908.0 2908 D On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person. Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. Based on a plan statement as of the end of the most recent fiscal quarter. All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Each restricted stock unit converts into one share of common stock upon vesting. The restricted stock unit vests in three equal annual installments beginning on May 1, 2018. ONE OF TWO (1 OF 2) FORM 4s BEING FILED TO REPORT TRANSACTIONS OCCURRING ON NOVEMBER 20, 2019. /s/ Lisa A. Atkins, attorney-in-fact for Nadim Ahmed 2019-11-27